Welcome to our dedicated page for Bright Minds Biosciences news (Ticker: DRUG), a resource for investors and traders seeking the latest updates and insights on Bright Minds Biosciences stock.
Bright Minds Biosciences Inc. (DRUG) generates news flow centered on its clinical-stage neuroscience pipeline and capital markets activity. As a biotechnology company focused on neurological and psychiatric disorders, its announcements frequently cover clinical trial milestones, data readouts and new program launches for conditions such as drug-resistant epilepsy, developmental and epileptic encephalopathies (DEE), Prader-Willi Syndrome (PWS), depression and other central nervous system disorders.
Recent news has highlighted topline Phase 2 results from the BREAKTHROUGH trial of BMB-101 in adult patients with drug-resistant absence seizures and DEE. The company reported that the study met primary efficacy endpoints in both cohorts, with seizure reductions and a safety and tolerability profile it describes as favorable. Updates have also included details on REM sleep findings in absence seizure patients and plans to prepare global registrational trials in absence seizures and DEE.
Investors following DRUG news will also see coverage of Bright Minds’ expansion into PWS, including initiation of the NOVA Phase 2a study of BMB-101 in PWS patients and nomination of BMB-105 as a new clinical candidate. The company has announced additions to its scientific advisory board featuring recognized PWS experts, along with explanations of the NOVA study design and its focus on hyperphagia-related behaviors and neurobehavioral symptoms.
Another recurring news theme is preclinical data from its serotonergic agonist platform, such as reports that BMB-201 outperformed sumatriptan in a validated vascular headache model. Capital markets updates, including the launch, pricing and closing of a US$175 million public offering of common shares under a Form F-3 shelf registration, also feature prominently. Readers who monitor this page can review these clinical, scientific and financing developments as Bright Minds advances its CNS-focused pipeline.
Bright Minds Biosciences (NASDAQ: DRUG) has announced promising preclinical results for BMB-201 in treating vascular headaches. The compound demonstrated superior performance compared to sumatriptan in a validated rat model study.
Key findings show that BMB-201 achieved statistically significant reductions in facial mechanical allodynia, with greater effect sizes than sumatriptan across multiple timepoints. In male subjects, BMB-201 showed 86% efficacy vs. sumatriptan's 81% at 1 hour, and 53-64% vs. 44% at 2 hours. In females, BMB-201 achieved 76-100% efficacy vs. sumatriptan's 56% at 1 hour, and 80% vs. 63% at 2 hours.
Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders, has announced its participation in four upcoming conferences in August and September 2025.
The conferences include the 36th International Epilepsy Congress in Lisbon (Aug 30-Sep 3), Cantor Global Healthcare Conference (Sep 5), H.C. Wainwright Global Investment Conference (Sep 9), and Baird Global Healthcare Conference (Sep 10). A live webcast will be available for the Cantor event through the company's investor relations website, with replay accessible for 60 days.
Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders, has announced its participation in the 2025 Jefferies Global Healthcare Conference in New York City. CEO Ian McDonald and CSO Jan Torleif Pedersen will present on Thursday, June 5, 2025, at 8:10 AM ET.
The presentation will be available via webcast on the company's investor relations website, with replay access for 60 days. Investors can schedule one-on-one meetings through Jefferies representatives.
Bright Minds Biosciences (NASDAQ: DRUG) has announced positive results from its DBA/2 mouse model study evaluating BMB-101, its novel 5-HT2C Gq-protein biased agonist. The study demonstrated that BMB-101 completely eliminated drop attacks in the DBA/2 mouse model and achieved 100% survival rate by reversing brainstem serotonin deficits and preventing seizure-induced respiratory arrest.
The DBA/2 mouse model is particularly significant as it replicates phenomena such as tonic/clonic seizures, drop attacks, and sudden unexpected death in epilepsy (SUDEP). These findings are crucial as SUDEP is the leading cause of seizure-related premature death, especially in drug-resistant epilepsy patients. For Dravet syndrome patients, the risk of premature death is estimated at 15-20%, with over half attributed to SUDEP.
Bright Minds Biosciences (NASDAQ: DRUG) has announced a virtual R&D Day scheduled for May 20, 2025, from 10:00 am to 11:30 am ET. The event will spotlight the company's focus on absence seizures and their ongoing BREAKTHROUGH study - a Phase 2 clinical trial evaluating BMB-101.
The webcast will feature presentations from Key Opinion Leaders (KOLs) in epilepsy research, examining the unmet needs in epilepsy patients. The BREAKTHROUGH study specifically evaluates the safety, tolerability, and efficacy of BMB-101 in adult patients with classic Absence Epilepsy and Developmental and Epileptic Encephalopathy (DEE).
The R&D Day will be accessible via webcast, with a replay available in the 'Investors' section under 'Events and Presentations' on the company's website.
Bright Minds Biosciences (NASDAQ: DRUG) has expanded its Scientific Advisory Board with five distinguished experts in epilepsy research. The new members include Dennis Dlugos, Jacqueline French, Terrence O'Brien, Jo Sourbron, and Joseph Sullivan, bringing extensive experience in epilepsy drug development and research.
This expansion aligns with the company's clinical focus on developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders. The company is currently conducting a Phase 2 BREAKTHROUGH study of BMB-101 in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).
Additionally, Bright Minds has granted stock options to purchase 161,000 common shares at US$35.00 per share and 600 Restricted Stock Units to directors, officers, and consultants. The options have a four-year term with vesting periods.
Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders, has announced its participation in three major healthcare conferences in March 2025.
The company's CEO Ian McDonald and senior management will attend:
- TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 1:10pm ET
- Leerink Partners Global Healthcare Conference in Miami on March 12, 2025 (one-on-one meetings)
- BIO-Europe Spring in Milan from March 17-19, 2025
Live and archived webcasts will be available on the company's investor relations website for 90 days following the events.
Bright Minds Biosciences (NASDAQ: DRUG) has appointed Stephen D. Collins, M.D., Ph.D., as Chief Medical Officer (CMO), effective immediately. Dr. Collins brings extensive experience in drug development and clinical expertise in epilepsy, replacing Mark A. Smith M.D., Ph.D., who will retire as Acting CMO but continue in an advisory role.
The appointment comes as the company advances its BREAKTHROUGH Study, a Phase 2 clinical trial evaluating BMB-101 in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE). Dr. Collins previously served as CEO of Biscayne Neurotherapeutics and Biscayne Pharmaceuticals, which was acquired by Supernus Pharmaceuticals. His track record includes leadership roles at Johnson & Johnson, Abbott Laboratories, and Ovation Pharmaceuticals, where he contributed to the development and approval of multiple anti-convulsant therapies.
Bright Minds Biosciences (NASDAQ: DRUG) announces two presentations at the American Epilepsy Society 2024 Annual Meeting in Los Angeles, December 6-10, 2024. The presentations will showcase data on BMB-101, their novel 5-HT2C agonist.
The first presentation by CSO Jan Torleif Pedersen will discuss Phase I study results on safety, tolerability, and pharmacokinetics of BMB-101. The second presentation by COO Alex Vasilkevich will focus on BMB-101's biased 5-HT2C agonism for epilepsy management. Both poster presentations are scheduled for Saturday, December 7, from 12:00 PM to 2:00 PM at South Hall H, Level 1.
FAQ
What is the current stock price of Bright Minds Biosciences (DRUG)?
What is the market cap of Bright Minds Biosciences (DRUG)?
